Clinical Trial Update: Efficacy and Safety of FP-1201-lyo (Interferon Beta-1a) in Prevention of Multi-Organ Failure on Patients After Open Surgery for a RAAA [Phase 2]

View source ↗

Summary

Phase 2 trial update on FP-1201-lyo (Interferon Beta-1a) for prevention of multi-organ failure after open surgery for ruptured abdominal aortic aneurysm; study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multi-organ Failure
• Preventive Medicine

Drugs mentioned

• FP-1201-lyo (Interferon Beta-1a)

Snippet

Sponsor: Faron Pharmaceuticals Ltd | Conditions: Preventive Medicine, Multi Organ Failure | Phase 2 | Status: TERMINATED | Results posted: 2021-01-14